Fri, February 10, 2023
Thu, February 9, 2023
Wed, February 8, 2023

Paul Matteis Maintained (VRTX) at Hold with Increased Target to $300 on, Feb 9th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-300-on-feb-9th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Paul Matteis of Stifel, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $289 to $300 on, Feb 9th, 2023.

Paul has made no other calls on VRTX in the last 4 months.



There are 17 other peers that have a rating on VRTX. Out of the 17 peers that are also analyzing VRTX, 6 agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Do Kim of "Piper Sandler" Maintained at Hold and Held Target at $296 on, Wednesday, February 8th, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $285 on, Wednesday, February 8th, 2023
  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Increased Target to $312 on, Wednesday, February 8th, 2023
  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $303 on, Tuesday, February 7th, 2023
  • Michael Yee of "Jefferies" Downgraded from Strong Buy to Hold and Held Target at $340 on, Monday, December 19th, 2022
  • Brian Skorney of "Baird" Maintained at Hold and Held Target at $280 on, Monday, October 31st, 2022


These are the ratings of the 11 analyists that currently disagree with Paul


  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $375 on, Wednesday, February 8th, 2023
  • David Risinger of "SVB Leerink" Maintained at Buy with Decreased Target to $365 on, Wednesday, February 8th, 2023
  • Evan Seigerman of "BMO Capital" Maintained at Buy and Held Target at $355 on, Wednesday, February 8th, 2023
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $342 on, Wednesday, February 8th, 2023
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $326 on, Wednesday, February 8th, 2023
  • Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $340 on, Thursday, November 17th, 2022
  • Hartaj Singh of "Oppenheimer" Maintained at Buy and Held Target at $350 on, Friday, November 11th, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $442 on, Monday, October 31st, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $335 on, Friday, October 28th, 2022
  • Phil Nadeau of "TD Cowen" Maintained at Buy with Increased Target to $330 on, Friday, October 28th, 2022
  • Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $327 on, Monday, October 24th, 2022

Publication Contributing Sources